Quest Diagnostics (MEX:DGX) Cyclically Adjusted Revenue per Share: MXN1,599.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:DGX Quest Diagnostics Inc MEX:DGX
71 GF Score
Price MXN3,624.00
GF Value MXN3,288.23
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Quest Diagnostics Cyclically Adjusted Revenue per Share?

Quest Diagnostics MEX:DGX 71 Cyclically Adjusted Revenue per Share is MXN1,599.35 as of Mar. 2026. GuruFocus rates MEX:DGX with a GF Score™ of 71/100 and a GF Value™ of MXN3,288.23 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Quest Diagnostics's adjusted revenue per share for the three months ended in Mar. 2026 was MXN466.113. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN1,599.35 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Quest Diagnostics's average Cyclically Adjusted Revenue Growth Rate was 6.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Quest Diagnostics was 10.00% per year. The lowest was 4.30% per year. And the median was 7.10% per year.

As of today (2026-07-21), Quest Diagnostics's current stock price is MXN3624.00. Quest Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN1,599.35. Quest Diagnostics's Cyclically Adjusted PS Ratio of today is 2.27.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Quest Diagnostics was 2.78. The lowest was 1.36. And the median was 2.05.


Quest Diagnostics  (MEX:DGX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Quest Diagnostics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3624.00/1599.35
=2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Quest Diagnostics was 2.78. The lowest was 1.36. And the median was 2.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Quest Diagnostics Cyclically Adjusted Revenue per Share Related Terms


Quest Diagnostics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Quest Diagnostics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Diagnostics Cyclically Adjusted Revenue per Share Chart

Quest Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,312.43 1,126.78 1,326.01 1,479.39 1,536.66

Quest Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,347.44 1,522.20 1,490.03 1,536.66 1,599.35

MEX:DGX vs LH, MTD, GH: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Quest Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest Diagnostics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Quest Diagnostics's Cyclically Adjusted PS Ratio falls into.


MEX:DGX
71GF Score
Quest Diagnostics Inc MEX:DGX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quest Diagnostics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Quest Diagnostics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=466.113/330.2130*330.2130
=466.113

Current CPI (Mar. 2026) = 330.2130.

Quest Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 248.230 241.018 340.094
201609 256.672 241.428 351.063
201612 231.385 241.432 316.471
201703 242.640 243.801 328.640
201706 240.669 244.955 324.435
201709 240.591 246.819 321.881
201712 261.626 246.524 350.442
201803 246.243 249.554 325.832
201806 271.276 251.989 355.487
201809 254.200 252.439 332.517
201812 259.775 251.233 341.440
201903 269.718 254.202 350.369
201906 275.845 256.143 355.612
201909 281.864 256.759 362.500
201912 267.091 256.974 343.213
202003 316.461 258.115 404.857
202006 310.081 257.797 397.184
202009 449.237 260.280 569.940
202012 439.087 260.474 556.648
202103 411.848 264.877 513.437
202106 399.687 271.696 485.770
202109 456.312 274.310 549.306
202112 450.323 278.802 533.362
202203 429.650 287.504 493.475
202206 414.701 296.311 462.148
202209 423.779 296.808 471.474
202212 395.515 296.797 440.046
202303 371.825 301.836 406.782
202306 351.600 305.109 380.529
202309 350.670 307.789 376.218
202312 346.760 306.746 373.288
202403 350.596 312.332 370.668
202406 392.083 314.175 412.098
202409 433.535 315.301 454.039
202412 471.231 315.605 493.042
202503 480.134 319.799 495.769
202506 460.066 322.561 470.980
202509 457.144 324.800 464.763
202512 447.115 324.054 455.613
202603 466.113 330.213 466.113

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN1,599.35 mean?
Quest Diagnostics (MEX:DGX) has a Cyclically Adjusted Revenue per Share of MXN1,599.35 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Quest Diagnostics and its competitors.
Is Quest Diagnostics' Cyclically Adjusted Revenue per Share too high?
Quest Diagnostics' current Cyclically Adjusted Revenue per Share is MXN1,599.35. Overall, Quest Diagnostics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Cyclically Adjusted Revenue per Share compare to LH and MTD?
Quest Diagnostics' Cyclically Adjusted Revenue per Share of MXN1,599.35 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current Cyclically Adjusted Revenue per Share is MXN1,599.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (MEX:DGX) is currently considered Fairly Valued. The stock's GF Value™ is MXN3,288.23, compared to a current price of MXN3,624.00 — trading 10.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN1,599.35. Quest Diagnostics' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Quest Diagnostics (MEX:DGX), the current Cyclically Adjusted Revenue per Share is MXN1,599.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Quest Diagnostics (MEX:DGX) Overvalued in 2026?

Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued. The current stock price of MXN3,624.00 is trading 10.2% above its estimated GF Value™ of MXN3,288.23. GuruFocus considers Quest Diagnostics to be Fairly Valued.

Key valuation signals for MEX:DGX:

  • Cyclically Adjusted Revenue per Share: MXN1,599.35
  • GF Value™: MXN3,288.23 vs. price of MXN3,624.00 (10.2% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the MEX:DGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Quest Diagnostics Business Description

Address 500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
71GF Score

Get the complete analysis for MEX:DGX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,624.00
Price
MXN3,288.23
GF Value